Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review

PURPOSEBlockage of PD-1 with drugs such as nivolumab (Nivo) and pembrolizumab (Pembro) has been successfully implemented in the treatment of Hodgkin lymphoma among other types of tumors. Exorbitant costs hinder access for many patients living in low- and middle-income countries (LMICs). Dose reducti...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Héctor A. Vaquera-Alfaro, José Emiliano Montelongo-Cepeda, Antonio Vega-Mateos, Anahí Morales-Pedraza, Haydeé Verduzco-Aguirre, David Gómez Almaguer, Luis Villela, Perla R. Colunga-Pedraza
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society of Clinical Oncology 2025-05-01
Edice:	JCO Global Oncology
On-line přístup:	https://ascopubs.org/doi/10.1200/GO-24-00538
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!